1. Home
  2. AXGN vs PHVS Comparison

AXGN vs PHVS Comparison

Compare AXGN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

HOLD

Current Price

$33.29

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.15

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXGN
PHVS
Founded
N/A
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AXGN
PHVS
Price
$33.29
$26.15
Analyst Decision
Strong Buy
Buy
Analyst Count
9
9
Target Price
$33.67
$39.44
AVG Volume (30 Days)
1.0M
138.4K
Earning Date
02-24-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$214,709,000.00
N/A
Revenue This Year
$21.98
N/A
Revenue Next Year
$15.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.72
N/A
52 Week Low
$9.22
$11.51
52 Week High
$36.00
$29.80

Technical Indicators

Market Signals
Indicator
AXGN
PHVS
Relative Strength Index (RSI) 49.68 51.19
Support Level $30.98 $25.69
Resistance Level $35.65 $27.59
Average True Range (ATR) 1.70 1.41
MACD -0.27 -0.09
Stochastic Oscillator 43.43 49.81

Price Performance

Historical Comparison
AXGN
PHVS

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: